Breadcrumb

DSI Business Development

Daiichi Sankyo Business Development

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets. With over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people.

In addition to a strong portfolio of medicines for hypertension and thrombotic disorders, under the Group’s 2025 Vision to become a “Global Pharma Innovator with a Competitive Advantage in Oncology”, Daiichi Sankyo Research and Development is primarily focused on bringing forth novel therapies in oncology, including immuno-oncology, with additional focus on new horizon areas, such as pain management, neurodegenerative diseases, heart and kidney conditions, and other rare diseases.

To reinforce the competitiveness of research in these areas, we are partnering on promising products that complement our in-house portfolio and will help us achieve long-term growth.  With a long-history of effective collaboration, our strategy involves partnering on specific aspects of research, development and/or commercialization. Our key areas of interest are:

Oncology

Novel biological approaches to cancer therapy

  • Novel monoclonal antibodies that would be good candidates for combination with our proprietary antibody-drug conjugate technology (ADC) that has been validated in the clinic (novel linker and payload ADC technology)
  • Biologics or molecular targets for genes/proteins that either control tumor cell proliferation, cause resistance to anti-tumor therapies, or allow tumor cells to escape from immune destruction
  • Cancer immunotherapy research focusing on inactivation of inhibitory/regulatory cells or activation of effector cells

Novel small molecule therapeutics focusing on epigenetics, cancer metabolism or cancer micro-environment

  • Novel targets/agents that complement or enhance the efficacy of our compounds being developed in acute myeloid leukemia (AML)
  • Novel targets for epigenetic factors that cause tumor regression in vivo
  • Small molecule modulators (inhibitors or activators) or novel targets of tumor immuno-suppression
  • Programs focusing on driver or resistance mutations (including fusion and variant-specific inhibitors)

Adoptive T cell therapy

  • Potentiate T cells to overcome the immuno-suppressive tumor microenvironment and elicit intrinsic immunity
  • Induced pluripotent stem cell (iPSC)-derived T cells comparable to native T cells in terms of cell killing, tumor infiltration, and cytokine production

 

New Horizon Therapeutic Areas

Novel Mechanisms of Action (MOAs) for Pain Management

  • Innovative targets/pathways for refractory pain (mixed or chronic) and chronic pain formation/transition
  • Targets/compounds for treating chemotherapy-induced peripheral neuropathy (CIPN)
  • Non-opioid pain pathway modifying targets/compounds cross-talking with opioid signaling

Novel approaches for the treatment of cardiovascular disease

  • Novel targets for acute/chronic heart failure, arrhythmia (persistent atrial fibrillation (AF)), stroke/transient ischemic attack (TIA), and kidney disease
  • Basic and translational research focused on the mechanisms underlying peripheral arterial disease (PAD)

Degenerative diseases in the central and peripheral nervous system

  • Novel targets to address vision loss from retinal degeneration
  • Mechanisms and pathways underlying sensory-neural hearing loss
  • Regeneration of neuronal and sensory cells and protein degradation/trafficking in neurons

Novel therapeutic targets and approaches for the gut microbiome that can modulate disease outcome

  • Small molecule therapeutics for gut microbiome-related diseases (i.e., irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), nonalcoholic steatohepatitis (NASH) and Celiac Disease)

Cell Therapeutics for serious diseases including Stroke/TIA, PAD/critical limb ischemia (CLI) and Hepatic Cirrhosis

  • Novel somatic stem/progenitor cells (SSCs/PCs) or pluripotent stem cell-derived cells (PSC-DCs)
  • Technologies for cell/gene modifications that improve cell therapeutic effects and/or reduce immunogenicity

Therapeutics for Rare Genetic Diseases (congenital metabolic diseases, neuromuscular diseases, etc.) due to a single gene mutation, and novel gene therapy vector approaches

Novel therapies for hematological diseases, especially for anemic disorders with erythropoietin resistance

 

Regional Commercial Interests

Japan

Late-stage or marketed products in Central Nervous System (CNS), Cardiovascular (CV) or Oncology for Japan commercialization

United States

Late-stage or marketed products/pipeline in  Pain or Specialty Care for US commercialization

European Union

Late-stage or marketed products in Specialty Care for EU commercialization

 

Partner with Daiichi Sankyo

We expect our employees to demonstrate a passion and drive that is consistent with our company's strategy and vision. Do you share these values? Are you interested in learning how to partner with Daiichi Sankyo? Please contact us to start a conversation about how we can work together to improve patient lives through the development of high-quality pharmaceutical products.

We have business development colleagues located globally, in Tokyo, Japan, in the United States (Basking Ridge, New Jersey), and in Europe (Munich, Germany). Please submit your licensing or alliance proposal for consideration.

PP-US-NP-0276 09/2017

Company Culture More Stories

Learn More

Who We Are

As the U.S. subsidiary of a global pharmaceutical innovator, Daiichi Sankyo, Inc. draws on a rich heritage of innovation, integrity and accountability.

read more ...

Business Development Helpful Resources